CN103356967A - Chinese herbal compound extract with effect of resisting proliferation of mammary gland, and preparation method thereof - Google Patents
Chinese herbal compound extract with effect of resisting proliferation of mammary gland, and preparation method thereof Download PDFInfo
- Publication number
- CN103356967A CN103356967A CN2013103261564A CN201310326156A CN103356967A CN 103356967 A CN103356967 A CN 103356967A CN 2013103261564 A CN2013103261564 A CN 2013103261564A CN 201310326156 A CN201310326156 A CN 201310326156A CN 103356967 A CN103356967 A CN 103356967A
- Authority
- CN
- China
- Prior art keywords
- parts
- alcohol
- extract
- eluent
- compound extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000284 extract Substances 0.000 title claims abstract description 72
- 150000001875 compounds Chemical class 0.000 title claims abstract description 54
- 210000005075 mammary gland Anatomy 0.000 title claims abstract description 54
- 230000000694 effects Effects 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000035755 proliferation Effects 0.000 title abstract 3
- 239000003814 drug Substances 0.000 claims abstract description 51
- 238000000605 extraction Methods 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 80
- 239000007788 liquid Substances 0.000 claims description 73
- 206010020718 hyperplasia Diseases 0.000 claims description 45
- 239000003480 eluent Substances 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000000341 volatile oil Substances 0.000 claims description 25
- 239000000706 filtrate Substances 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 19
- 241001489978 Eupolyphaga Species 0.000 claims description 18
- 229920000858 Cyclodextrin Polymers 0.000 claims description 17
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 17
- 239000003463 adsorbent Substances 0.000 claims description 11
- 239000011347 resin Substances 0.000 claims description 11
- 229920005989 resin Polymers 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000008367 deionised water Substances 0.000 claims description 7
- 229910021641 deionized water Inorganic materials 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000001179 sorption measurement Methods 0.000 claims description 7
- 238000001256 steam distillation Methods 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 5
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 229940126701 oral medication Drugs 0.000 abstract description 3
- 230000004069 differentiation Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000131329 Carabidae Species 0.000 abstract 1
- 241000935235 Fritillaria meleagris Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 240000004980 Rheum officinale Species 0.000 abstract 1
- 235000008081 Rheum officinale Nutrition 0.000 abstract 1
- 244000178320 Vaccaria pyramidata Species 0.000 abstract 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 description 16
- 241000700159 Rattus Species 0.000 description 14
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000186 progesterone Substances 0.000 description 4
- 229960003387 progesterone Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000004695 acinic cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940083546 estradiol 0.5 mg Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000543 ovarian dysfunction Toxicity 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a Chinese herbal compound extract with an effect of resisting proliferation of mammary gland, and a preparation method thereof. The Chinese herbal compound extract is prepared by the following raw materials by weight: 10-20 parts of radix bupleuri, 10-20 parts of rhizoma cyperi, 5-15 parts of rheum officinale, 5-15 parts of pericarpium citri reticulatae viride, 5-15 parts of rhizoma chuanxiong, 5-15 parts of rhizoma curcumae, 5-15 parts of fritillary bulb, 10-20 parts of angelica sinensis, 10-20 parts of white peony root, 5-15 parts of ground beetle and 5-15 parts of cowherb seed. The Chinese herbal compound extract is prepared by a scientific formula, treats based on syndrome differentiation according to the theory of traditional Chinese medicine. Active components and an optimum preparation process are screened out by adopting a modern chemical component extraction separation and a pharmacological experiment tracking method. Pharmacological experiments show that the Chinese herbal compound extract provided by the invention has very good effect for treating the proliferation of the mammary gland, and has no toxic and side effect. The preparation method provided by the invention is stable in process and good in repeatability. The prepared extract is stable in quality. A plurality of oral drug preparations can be prepared and the oral drug preparations are convenient for clinic use.
Description
Technical field
The present invention relates to a kind of Chinese medicine compound, specifically relate to a kind of Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect and preparation method thereof.
Background technology
Cyclomastopathy is common women's surgical diseases, its sickness rate accounts for 75% of whole cystic hyperplasia of breast, accounts for the women of child-bearing age's 40%, has a strong impact on numerous women's physical and mental health, be that more this disease has the danger of the breast carcinoma of developing into, cause that the probability of canceration accounts for 2～4%.Thereby the active treatment cyclomastopathy, improve the WomanHealth level, reduce canceration rate and have very great significance.
Modern medicine thinks, cyclomastopathy be because of endocrine dysfunction, ovarian dysfunction, cause body inner estrogen level to increase or increased activity, due to progesterone level descends.Obvious for the heavier or local tuberosity of cyclomastopathy pain, the obvious patient of tenderness, clinical versatility hormonotherapy and incretotherapy.Such as Progesterone, danazol, tamoxifen, bromocriptine etc.With the said method treatment, though curative effect is good, side effect is larger, and drug price is expensive, can not adhere to for a long time treatment, and recurrent pain after the drug withdrawal, lump increases, and finally still needs continual cure-excision.Especially may further disturb the balance between the human hormone after gonadal hormone is used, increase the probability of canceration.In sum, modern medicine is treated this disease at present take operation as main, and medicine is auxiliary.No matter be excision, Drug therapy, have all that expense is high, side effect is obvious, wound face is large, a shortcoming such as easy recurrence after operation or the drug withdrawal.Therefore doctor trained in Western medicine there is no desirable solution route and Therapeutic Method to this disease.
Motherland's medicine just has a deep understanding since ancient times to cyclomastopathy, belongs to the category of " nodules of the breast ", " newborn painful abdominal mass ", " nodule in the breast ", and the syndrome of relevant " nodules of the breast " is discussed from " Huatuo's Zhongzang classic " of Han dynasty and all is documented to the Qing Dynasty " surgeon is complete works of ".Think that this is sick relevant with Nervous and Mental Factors, mainly and the internal organs such as liver,kidney,spleen dirty in close relations.The cause of disease, pathogenesis are due to feelings will internal injury, qi depression to blood stasis, Chong and Ren channel disorder, the expectorant stasis of blood are condensed, newborn network is obstructed.Liver controlling conveyance and dispersion should be transferred to reach, the Liver Channel stagnation of QI, QI and blood week loss degree, coagulation of QI-blood; Worry impairing spleen, spleen fortune mistake department, the turbid interior life of expectorant; Turbid and the blood stasis of expectorant is tied mutually to hinder in newborn network and is formed nodules of the breast.Adopt Chinese medicine that cyclomastopathy is treated, have the advantages such as curative effect is reliable, side effect is little.
Summary of the invention
Goal of the invention: the objective of the invention is to solve the deficiencies in the prior art, provide a kind of curative effect reliable, security performance is high, and untoward reaction is low, and price is easy to Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect of vast sufferer acceptance and preparation method thereof.
Technical scheme: in order to realize above purpose, the technical scheme that the present invention takes is:
A kind of Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect, it is made by the raw material of following parts by weight:
10～20 parts of Radix Bupleuri, 10～20 parts of Rhizoma Cyperis, 5～15 parts of Radix Et Rhizoma Rhei, 5～15 parts on Pericarpium Citri Reticulatae Viride, 5～15 parts of Rhizoma Chuanxiongs, 5～15 parts of Rhizoma Curcumae, 5～15 parts of Bulbus Fritillariae Thunbergiis, 10～20 parts of Radix Angelicae Sinensis, 10～20 parts of the Radix Paeoniae Albas, 5～15 parts of Eupolyphaga Seu Steleophagas, Semen Vaccariae 5-15 part.
As preferred version, the Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect of the present invention, it is prepared by following method:
A, get 10～20 parts of Radix Bupleuri, 5～15 parts of Radix et Rhizoma Rhei (processed with wine), 5～15 parts of Bulbus Fritillariae Thunbergiis, 10～20 parts of the Radix Paeoniae Albas, Semen Vaccariae (parched) and add water or C
1～3Alcohol extraction, extracting liquid filtering, filtrate is concentrated into 0.25g to 4g crude drug/mL medicinal liquid;
B, get 5～15 parts of 5～15 parts of Rhizoma Chuanxiongs, 5～15 parts of Rhizoma Curcumae, 10～20 parts of Radix Angelicae Sinensis, parch skin and adopt extraction by steam distillation, the volatile oil of acquisition adopts cyclodextrin inclusion compound; Extracting liquid filtering, it is 60%～80% alcohol that adding ethanol makes the concentration of ethanol, places precipitation, filters, and filtrate is concentrated into without the ethanol flavor, and thin up is to 0.25g to 4g crude drug/mL medicinal liquid again;
C, get the medicinal liquid that medicinal liquid that step a prepares and step b prepare, upper macroporous adsorbent resin after mixing, after the standing adsorption, being eluted to the stream eluent with deionized water is light color, discards eluent, then is 5%～20% C with concentration
1～3It is light color that alcohol is eluted to eluent as eluant, discards eluent, is 40%～90% C again with concentration
1～3The alcohol eluting is collected eluent, and the eluent reclaim under reduced pressure is removed C
1～3Alcohol is concentrated into 0.5g～2g crude drug/1ml medicinal liquid;
D, get 5～15 parts of Eupolyphaga Seu Steleophagas, add water or C
1～3Alcohol extraction, extracting liquid filtering, filtrate is concentrated into 0.5g～2g crude drug/1ml;
E, get the Eupolyphaga Seu Steleophaga that medicinal liquid that step c prepares and steps d prepare and extract the medicinal liquid mix homogeneously, concentrate drying is pulverized, the cyclodextrin of volatile oil clathrate mix homogeneously that gained extract powder and step b prepare, and get final product.The present invention screens by experiment and shows, the volatile oil component of Rhizoma Chuanxiong, Rhizoma Curcumae, Radix Angelicae Sinensis and Pericarpium Citri Reticulatae Viride has the effect of good resisting hyperplasia of mammary glands in the Chinese herbal compounds, and prior art is when preparing, do not keep the volatility active component, so the extract that the present invention prepares has the effect of better resisting hyperplasia of mammary glands.
As preferred version, above-described Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect, step a, c, the described C of d
1～3Alcohol is methanol, ethanol or propanol.
As preferred version, above-described Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect, the described cyclodextrin inclusion method of step b is: every milliliter of volatile oil is dissolved in 80 to the 100ml water with 8g to 10g beta-schardinger dextrin-, under 60 ℃ to 80 ℃ condition, stir 1 to 3 hour enclose.As preferred method, the described cyclodextrin inclusion method of step b is: every milliliter of volatile oil 8g beta-schardinger dextrin-, be dissolved in the 80ml water, and under 60 ℃ condition, stir 1 hour enclose.
As preferred version, above-described Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect, described macroporous adsorbent resin are D101(Cangzhou precious grace chemical industry company limited), HPD100(Cangzhou precious grace chemical industry company limited), X-5(Cangzhou precious grace chemical industry company limited) or AB-8(Cangzhou precious grace chemical industry company limited) macroporous adsorbent resin.
As preferred version, above-described Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect is got 5～15 parts of Eupolyphaga Seu Steleophagas, water or the C of 10 to 12 times of amounts
1～3Alcohol extraction 1 to 3 time, each 1 to 3 hour, extracting liquid filtering, filtrate is concentrated into 0.5g～2g crude drug/1ml.
Preparation method with Chinese medicinal compound extract of resisting hyperplasia of mammary glands effect provided by the invention, it may further comprise the steps:
A, get 5～15 parts of 10～20 parts of Radix Bupleuri, 5～15 parts of Radix et Rhizoma Rhei (processed with wine), 5～15 parts of Bulbus Fritillariae Thunbergiis, 10～20 parts of the Radix Paeoniae Albas, Semen Vaccariae (parched) and add water or C
1～3Alcohol extraction, extracting liquid filtering, filtrate is concentrated into 0.25g to 4g crude drug/mL medicinal liquid;
B, get 5～15 parts of 5～15 parts of Rhizoma Chuanxiongs, 5～15 parts of Rhizoma Curcumae, 10～20 parts of Radix Angelicae Sinensis, parch skin and adopt extraction by steam distillation, the volatile oil of acquisition adopts cyclodextrin inclusion compound; Extracting liquid filtering, it is 60%～80% alcohol that adding ethanol makes the concentration of ethanol, places precipitation, filters, and filtrate is concentrated into without the ethanol flavor, and thin up is to 0.25g to 4g crude drug/mL medicinal liquid again;
C, get the medicinal liquid that medicinal liquid that step a prepares and step b prepare, upper macroporous adsorbent resin after mixing, after the standing adsorption, being eluted to the stream eluent with deionized water is light color, discards eluent, then is 5%～20% C with concentration
1～3It is light color that alcohol is eluted to eluent as eluant, discards eluent, is 40%～90% C again with concentration
1～3The alcohol eluting is collected eluent, and the eluent reclaim under reduced pressure is removed C
1～3Alcohol is concentrated into 0.5g～2g crude drug/1ml medicinal liquid;
D, get 5～15 parts of Eupolyphaga Seu Steleophagas, add water or C
1～3Alcohol extraction, extracting liquid filtering, filtrate is concentrated into 0.5g～2g crude drug/1ml;
E, get the Eupolyphaga Seu Steleophaga that medicinal liquid that step c prepares and steps d prepare and extract the medicinal liquid mix homogeneously, concentrate drying is pulverized, the cyclodextrin of volatile oil clathrate mix homogeneously that gained extract powder and step b prepare, and get final product.The present invention screens by experiment and shows, the volatile oil component of Rhizoma Chuanxiong, Rhizoma Curcumae, Radix Angelicae Sinensis and parch skin has the effect of good resisting hyperplasia of mammary glands in the Chinese herbal compounds, and prior art is when preparing, do not keep the volatility active component, so the extract that the present invention prepares has the effect of better resisting hyperplasia of mammary glands.
As preferred version, above-described preparation method with Chinese medicinal compound extract of resisting hyperplasia of mammary glands effect, wherein step a, c, the described C of d
1～3Alcohol is methanol, ethanol or propanol.
As preferred version, above-described preparation method with Chinese medicinal compound extract of resisting hyperplasia of mammary glands effect, the described cyclodextrin inclusion method of step b is: every milliliter of volatile oil is with 8g to 10g beta-schardinger dextrin-, be dissolved in 80 to the 100ml water, under 60 ℃ to 80 ℃ condition, stir 1 to 3 hour enclose.As preferred method, the described cyclodextrin inclusion method of step b is: every milliliter of volatile oil 8g beta-schardinger dextrin-, be dissolved in the 80ml water, and under 60 ℃ condition, stir 1 hour enclose.
The application of Chinese medicinal compound extract in preparation resisting hyperplasia of mammary glands medicine with resisting hyperplasia of mammary glands effect provided by the invention.
The above-described application of Chinese medicinal compound extract in preparation resisting hyperplasia of mammary glands medicine with resisting hyperplasia of mammary glands effect, Chinese medicinal compound extract and pharmaceutically acceptable carrier are prepared into oral liquid, granule, capsule, tablet, drop pill, the soft capsule medicine.
When the Chinese medicinal compound extract of resisting hyperplasia of mammary glands effect provided by the invention is made tablet, the extract of each raw material and lactose or corn starch, add magnesium stearate lubricant when needing, mix homogeneously, granulate, then tabletting is made tablet.
When the Chinese medicinal compound extract of resisting hyperplasia of mammary glands effect provided by the invention is made capsule the extract of each raw material and carrier lactose or corn starch mix homogeneously, granulate, the then encapsulated capsule of making.
During the Chinese medicinal compound extract granulation agent of resisting hyperplasia of mammary glands effect provided by the invention, the extract of each raw material and diluent lactose or corn starch mix homogeneously, granulate, drying, granulation agent.
When the Chinese medicinal compound extract of resisting hyperplasia of mammary glands effect provided by the invention is made oral liquid, the extract of each raw material is added the purified water dissolving, add syrup, regulate pH, make oral liquid.
Beneficial effect: the Chinese medicinal compound extract of resisting hyperplasia of mammary glands effect provided by the invention has the following advantages:
The present invention is according to Chinese medical theory, and determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs is formulated the present invention through scientific composition, and adopts modern chemistry component extraction separation and pharmacological evaluation tracking, filters out active component and best preparation technology thereof.
And preparation method provided by the invention, process stabilizing, favorable reproducibility, the extract for preparing, steady quality, easy to use, can prepare multiple oral drug preparation, convenient clinical taking.And pharmacological evaluation shows that Chinese medicinal compound extract provided by the invention has the effect of good treatment cyclomastopathy, has no side effect.
The specific embodiment
Further illustrate the present invention below in conjunction with specific embodiment, should understand these embodiment only is used for explanation the present invention and is not used in and limits the scope of the invention, after having read the present invention, those skilled in the art all fall within the application's claims limited range to the modification of the various equivalent form of values of the present invention.
Embodiment 1
A kind of preparation method with Chinese medicinal compound extract of resisting hyperplasia of mammary glands effect, it may further comprise the steps:
A, the powder mixing of getting 12.5 parts of Radix Bupleuri, 8.34 parts of Radix et Rhizoma Rhei (processed with wine), 8.34 parts of Bulbus Fritillariae Thunbergiis, 12.5 parts of the Radix Paeoniae Albas, 8.34 parts of mistake 60 mesh sieves of Semen Vaccariae (parched), add 70% alcohol reflux 3 times, each 3h filters, filtrate is concentrated into without the alcohol flavor, and thin up is to 0.25g to 4g crude drug/mL medicinal liquid again;
B, get 8.34 parts of 12.5 parts of Rhizoma Cyperis, 8.34 parts of Rhizoma Chuanxiongs, 8.34 parts of Rhizoma Curcumae, 12.5 parts of Radix Angelicae Sinensis, Pericarpium Citri Reticulatae Viride and be mixed in proportion, add the water of 12 times of medical material gross weights, adopt extraction by steam distillation, get volatile oil component; It is 0.75g/ml that extracting liquid filtering, filtrate are concentrated into the crude drug amount, and then adding ethanol to determining alcohol is 70%, staticly settles 24h, filters, and filtrate decompression concentrates to get medicinal liquid;
Every milliliter of use of volatile oil part 8g beta-schardinger dextrin-is dissolved in the 80ml water, and inclusion, stirring are 1 hour under 60 ℃ condition, and volatile oil inclusion rate reaches 82.5%.；
C, Radix Bupleuri, Radix et Rhizoma Rhei (processed with wine), Bulbus Fritillariae Thunbergii, the Radix Paeoniae Alba, the extracting solution of Semen Vaccariae (parched)-1 and Rhizoma Cyperi, Rhizoma Chuanxiong, Rhizoma Curcumae, Radix Angelicae Sinensis, the refined liquid of Pericarpium Citri Reticulatae Viride-2 is mixed, thin up to crude drug amount is 0.5g/ml, upper AB-8 macroporous adsorbent resin, after the standing adsorption 12, being eluted to the stream eluent with deionized water is light color, discard eluent, then being eluted to eluent with 20% ethanol as eluant is light color, discard eluent, use 80% ethanol elution of 12 times of loading volumes again, collect eluent, the eluent reclaim under reduced pressure is removed ethanol, be concentrated into the 1ml concentrated solution and be equivalent to the 1.5g crude drug, cooling;
D, get 8.34 parts of Eupolyphaga Seu Steleophagas, add 12 times of medical material weight water extraction 2 times, each 2h filters, merging filtrate is concentrated into the 1ml concentrated solution and is equivalent to the 1.5g crude drug, cooling;
E, get the Eupolyphaga Seu Steleophaga that medicinal liquid that step c prepares and steps d prepare and extract the medicinal liquid mix homogeneously, concentrate drying is pulverized, the cyclodextrin of volatile oil clathrate mix homogeneously that gained extract powder and step b prepare, and get final product.
F, get step e extract and add lactose, add magnesium stearate lubricant, mix homogeneously, granulate, then tabletting is made tablet.
Embodiment 2
Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect of the present invention, it is prepared by following method:
A, get 20 parts of Radix Bupleuri, 15 parts of Radix et Rhizoma Rhei (processed with wine), 15 parts of Bulbus Fritillariae Thunbergiis, 20 parts of the Radix Paeoniae Albas, 15 parts of Semen Vaccariae (parched)s, add respectively the water extraction 3 times of 8,10 and 12 times of amounts, each 2 hours, extracting liquid filtering, filtrate is concentrated into 0.25g to 4g crude drug/mL medicinal liquid;
B, get 15 parts of 15 parts of Rhizoma Chuanxiongs, 15 parts of Rhizoma Curcumae, 20 parts of Radix Angelicae Sinensis, parch skin and adopt extraction by steam distillation, the volatile oil of acquisition, every milliliter of volatile oil 8g beta-schardinger dextrin-is dissolved in the 80ml water, under 60 ℃ condition, stirs 1 hour enclose; Extracting liquid filtering, it is 80% alcohol that adding ethanol makes the concentration of ethanol, places precipitation, filters, and filtrate is concentrated into without the ethanol flavor, and thin up is to 0.25g to 4g crude drug/mL medicinal liquid again;
C, get the medicinal liquid that medicinal liquid that step a prepares and step b prepare, upper D101 macroporous adsorbent resin after mixing, after the standing adsorption, being eluted to the stream eluent with deionized water is light color, discards eluent, then be that to be eluted to eluent as eluant be light color for 5%～20% ethanol with concentration, discarding eluent, is 40%～90% ethanol elution again with concentration, collects eluent, the eluent reclaim under reduced pressure is removed ethanol, is concentrated into 0.5g～2g crude drug/1ml medicinal liquid;
D, get 15 parts of Eupolyphaga Seu Steleophagas, add the water extraction 2 times of 12 times of amounts, each 2 hours, extracting liquid filtering, filtrate is concentrated into 0.5g～2g crude drug/1ml;
E, get the Eupolyphaga Seu Steleophaga that medicinal liquid that step c prepares and steps d prepare and extract the medicinal liquid mix homogeneously, 60 ℃ of drying under reduced pressure are pulverized, the cyclodextrin of volatile oil clathrate mix homogeneously that gained extract powder and step b prepare, and get final product.
F, get step e extract and add appropriate amount of starch or cyclodextrin, granulate the encapsulated capsule of making.
Embodiment 3
Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect of the present invention, it is prepared by following method:
A, get 10 parts of Radix Bupleuri, 5 parts of Radix et Rhizoma Rhei (processed with wine), 5 parts of Bulbus Fritillariae Thunbergiis, 10 parts of the Radix Paeoniae Albas, 5 parts of Semen Vaccariae (parched)s, add 10 times of amounts, concentration is 70% ethanol extraction 3 times, each 2 hours, and extracting liquid filtering, filtrate is concentrated into 0.25g to 4g crude drug/mL medicinal liquid;
B, get 5 parts of 5 parts of Rhizoma Chuanxiongs, 5 parts of Rhizoma Curcumae, 10 parts of Radix Angelicae Sinensis, parch skin and adopt extraction by steam distillation, the volatile oil of acquisition, every milliliter of volatile oil 8g beta-schardinger dextrin-is dissolved in the 80ml water, under 60 ℃ condition, stirs 1 hour enclose; Extracting liquid filtering, it is 60% alcohol that adding ethanol makes the concentration of ethanol, places precipitation, filters, and filtrate is concentrated into without the ethanol flavor, and thin up is to 0.25g to 4g crude drug/mL medicinal liquid again;
C, get the medicinal liquid that medicinal liquid that step a prepares and step b prepare, upper HPD100 macroporous adsorbent resin after mixing, after the standing adsorption, being eluted to the stream eluent with deionized water is light color, discards eluent, then be that to be eluted to eluent as eluant be light color for 5%～20% ethanol with concentration, discarding eluent, is 40%～90% ethanol elution again with concentration, collects eluent, the eluent reclaim under reduced pressure is removed ethanol, is concentrated into 0.5g～2g crude drug/1ml medicinal liquid;
D, get 5 parts of Eupolyphaga Seu Steleophagas, the concentration that adds 10 times of amounts is 75% ethanol extraction 2 times, each 3 hours, and extracting liquid filtering, filtrate is concentrated into 0.5g～2g crude drug/1ml;
E, get the Eupolyphaga Seu Steleophaga that medicinal liquid that step c prepares and steps d prepare and extract the medicinal liquid mix homogeneously, 60 ℃ of drying under reduced pressure are pulverized, the cyclodextrin of volatile oil clathrate mix homogeneously that gained extract powder and step b prepare, and get final product.
F, get step e extract and add the purified water dissolving, add syrup, regulate pH, make oral liquid.
Embodiment 4 Chinese medicinal compound extracts are on the impact research of rat mammary gland cyclomastopathy effect
1, laboratory animal modeling: getting body weight is 120 of the female not pregnant rats of 170～200g cleaning level SD, form hyperplasia of mammary gland model with estradiol and Progesterone combined induction, method is: except blank group intramuscular injection normal saline 0.25ml/kg, 1 times/day, injection 25 beyond the highest heavens continuously, all the other respectively organize equal intramuscular injection estradiol 0.5mg/kg, 1 times/day, continuous 20 days, then use intramuscular injection Progesterone 5mg/kg, 1 times/day, continuous 5 days instead.
2, experiment grouping: the modeling rat is pressed cyclomastopathy situation random packet and administration, the administration component is the newborn eliminating stagnation Capsules group (0.9g/kg) that disappears, the Chinese medicinal compound extract low dose group that the embodiment of the invention 1 prepares (2.7g crude drug amount/kg) and Chinese medicinal compound extract high dose group (8.1g/ crude drug amount kg), and the Chinese medicinal compound extract low dose group that the embodiment of the invention 2 prepares (2.7g crude drug amount/kg) and Chinese medicinal compound extract high dose group (8.1g crude drug amount/kg).Other establishes model group and blank group.Model group and blank group give corresponding normal saline, all the other each groups are by above-mentioned dosage gastric infusion, every day 1 time, continuous 20 days, and carry out following index determining: the breast height: after the experiment beginning, survey the 3rd pair of breast height of 1 rat with digital display calliper weekly.The mammary gland tissue pathology check: rat is got its mammary gland tissue after putting to death, be fixed in 10% formalin, and the routine paraffin wax embedding, slice thick 5 μ m, histopathologic examination is carried out in HE dyeing.
3, experimental result is as follows:
3.1 the impact on the rat breast height
After the beginning administration, survey weekly the breast height 1 time.The result shows: model group rat breast height and blank group relatively have notable difference (P ﹤ 0.05,0.01).Chinese medicinal compound extract high and low dose group and the model group that newborn eliminating stagnation Capsules group, the embodiment of the invention 1 and embodiment 2 prepare that disappear more all has the effect that reduces the breast height, with obvious (the P ﹤ 0.05 of model group comparing difference, 0.01), and prolong with administration time, effect is better, and concrete experimental result as shown in Table 1 and Table 2.
Each group of table 1 is on the impact of rats with left breast height
#P ﹤ 0.05, ##P ﹤ 0.01 compares with the blank group; * P ﹤ 0.05, and * * P ﹤ 0.01 compares with model group
Each group of table 2 is on the impact of rat right breast height
#P ﹤ 0.05, ##P ﹤ 0.01 compares with the blank group; * P ﹤ 0.05, and * * P ﹤ 0.01 compares with model group
3.2 the impact on the variation of rat mammary gland histopathology
Mammary gland is carried out semi-quantitative analysis, analyze content and comprise: the hyperplasia degree of the acinus par of each lobules of mammary gland, acinus secreting phenomenon, acinus and ductal epithelium.According to pathological changes by gently being designated as 0 minute (normal) to heavy degree, 1 minute (slightly), 2 minutes (moderate), 3 minutes (severe), 4 minutes (utmost point severe).
The result shows: blank group rat acinous cell is without hypertrophy, and conduit diameter is normal, sees a small amount of in the conduit or without secretions, epithelium is without hypertrophy.Model group rat mammary gland lobule acinus number increases, and the acinus volume increases, and with the blank group notable difference (P ﹤ 0.01) is arranged relatively.And the Chinese medicinal compound extract high and low dose group that disappear newborn eliminating stagnation group, the embodiment of the invention 1 and embodiment 2 prepare and model group are relatively, all can reduce the cyclomastopathy degree, with model group comparing difference obvious (P ﹤ 0.05,0.01), concrete experimental result sees Table 3.
Each group of table 3 is on the impact of rat mammary gland hyperplasia degree
| Group | Dosage (g/kg) | Number of animals (only) | Pathological score |
| Blank | - | 9 | 0.00±0.00 |
| Model | - | 10 | 1.00±0.76## |
| Newborn eliminating stagnation disappears | 0.9 | 9 | 0.57±0.98 |
| Embodiment 1 low dose group | 2.7 | 10 | 0.00±0.00** |
| Embodiment 1 high dose group | 8.1 | 9 | 0.11±0.33* |
| Embodiment 2 low dose group | 2.7 | 8 | 0.38±0.52 |
| Embodiment 2 high dose group | 8.1 | 9 | 0.00±0.00** |
##P ﹤ 0.01 compares * P ﹤ 0.05 with the blank group, and * * P ﹤ 0.01 compares with model group
Compare with the blank group, model group rat breast height increases, and lobules of mammary gland acinus number increases, and the acinus volume increases; The Chinese medicinal compound extract high and low dose group that the embodiment of the invention 1 and embodiment 2 prepare all can reduce the breast height, alleviates breast lesion; Demonstrated the effect of good resisting hyperplasia of mammary glands, and pathology detection to other internal organs without obvious damage, have safely and effectively and have a few, be expected to be developed to the medicine of new resisting hyperplasia of mammary glands.
The above only is preferred implementation of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the principle of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (9)
1. the Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect is characterized in that, it is made by the raw material of following parts by weight:
10 ~ 20 parts of Radix Bupleuri, 10 ~ 20 parts of Rhizoma Cyperis, 5 ~ 15 parts of Radix Et Rhizoma Rhei, 5 ~ 15 parts on Pericarpium Citri Reticulatae Viride, 5 ~ 15 parts of Rhizoma Chuanxiongs, 5 ~ 15 parts of Rhizoma Curcumae, 5 ~ 15 parts of Bulbus Fritillariae Thunbergiis, 10 ~ 20 parts of Radix Angelicae Sinensis, 10 ~ 20 parts of the Radix Paeoniae Albas, 5 ~ 15 parts of Eupolyphaga Seu Steleophagas, Semen Vaccariae 5-15 part.
2. the Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect according to claim 1 is characterized in that, it is prepared by following method:
A, get 10 ~ 20 parts of Radix Bupleuri, 5 ~ 15 parts of Radix Et Rhizoma Rhei, 5 ~ 15 parts of Bulbus Fritillariae Thunbergiis, 10 ~ 20 parts of the Radix Paeoniae Albas, Semen Vaccariae 5-15 part and add water or C
1 ~ 3Alcohol extraction, extracting liquid filtering, filtrate is concentrated into 0.25g to 4g crude drug/mL medicinal liquid;
B, get 5 ~ 15 parts of 5 ~ 15 parts of Rhizoma Chuanxiongs, 5 ~ 15 parts of Rhizoma Curcumae, 10 ~ 20 parts of Radix Angelicae Sinensis, Pericarpium Citri Reticulatae Viride and adopt extraction by steam distillation, the volatile oil of acquisition adopts cyclodextrin inclusion compound; Extracting liquid filtering, it is 60% ~ 80% alcohol that adding ethanol makes the concentration of ethanol, places precipitation, filters, and filtrate is concentrated into without the ethanol flavor, and thin up is to 0.25g to 4g crude drug/mL medicinal liquid again;
C, get the medicinal liquid that medicinal liquid that step a prepares and step b prepare, upper macroporous adsorbent resin after mixing, after the standing adsorption, being eluted to the stream eluent with deionized water is light color, discards eluent, then is 5% ~ 20% C with concentration
1 ~ 3It is light color that alcohol is eluted to eluent as eluant, discards eluent, is 40% ~ 90% C again with concentration
1 ~ 3The alcohol eluting is collected eluent, and the eluent reclaim under reduced pressure is removed C
1 ~ 3Alcohol is concentrated into 0.5g ~ 2g crude drug/1ml medicinal liquid;
D, get 5 ~ 15 parts of Eupolyphaga Seu Steleophagas, add water or C
1 ~ 3Alcohol extraction, extracting liquid filtering, filtrate is concentrated into 0.5g ~ 2g crude drug/1ml;
E, get the Eupolyphaga Seu Steleophaga that medicinal liquid that step c prepares and steps d prepare and extract the medicinal liquid mix homogeneously, concentrate drying is pulverized, and gets the cyclodextrin of volatile oil clathrate mix homogeneously that extract powder and step b prepare, and get final product.
3. the Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect according to claim 1 is characterized in that, step a, c, the described C of d
1 ~ 3Alcohol is methanol, ethanol or propanol.
4. the Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect according to claim 1, it is characterized in that, the described cyclodextrin inclusion method of step b is: every milliliter of volatile oil is with 8g to 10g beta-schardinger dextrin-, be dissolved in 80 to the 100ml water, under 60 ℃ to 80 ℃ condition, stir 1 to 3 hour enclose.
5. the Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect according to claim 1 is characterized in that, described macroporous adsorbent resin is D101, HPD100, X-5 or AB-8 macroporous adsorbent resin.
6. the Chinese medicinal compound extract with resisting hyperplasia of mammary glands effect according to claim 1 is characterized in that, gets 5 ~ 15 parts of Eupolyphaga Seu Steleophagas, the water of 10 to 12 times of amounts or C1 ~ 3 alcohol extractions 1 to 3 time, each 1 to 3 hour, extracting liquid filtering, filtrate is concentrated into 0.5g ~ 2g crude drug/1ml.
7. the preparation method with Chinese medicinal compound extract of resisting hyperplasia of mammary glands effect claimed in claim 2 is characterized in that may further comprise the steps:
A, get 10 ~ 20 parts of Radix Bupleuri, 5 ~ 15 parts of Radix Et Rhizoma Rhei, 5 ~ 15 parts of Bulbus Fritillariae Thunbergiis, 10 ~ 20 parts of the Radix Paeoniae Albas, Semen Vaccariae and add water or C
1 ~ 3Alcohol extraction, extracting liquid filtering, filtrate is concentrated into 0.25g to 4g crude drug/mL medicinal liquid;
B, get 5 ~ 15 parts of 5 ~ 15 parts of Rhizoma Chuanxiongs, 5 ~ 15 parts of Rhizoma Curcumae, 10 ~ 20 parts of Radix Angelicae Sinensis, Pericarpium Citri Reticulatae Viride and adopt extraction by steam distillation, the volatile oil of acquisition adopts cyclodextrin inclusion compound; Extracting liquid filtering, it is 60% ~ 80% alcohol that adding ethanol makes the concentration of ethanol, places precipitation, filters, and filtrate is concentrated into without the ethanol flavor, and thin up is to 0.25g to 4g crude drug/mL medicinal liquid again;
C, get the medicinal liquid that medicinal liquid that step a prepares and step b prepare, upper macroporous adsorbent resin after mixing, after the standing adsorption, being eluted to the stream eluent with deionized water is light color, discards eluent, then is 5% ~ 20% C with concentration
1 ~ 3It is light color that alcohol is eluted to eluent as eluant, discards eluent, is 40% ~ 90% C again with concentration
1 ~ 3The alcohol eluting is collected eluent, and the eluent reclaim under reduced pressure is removed C
1 ~ 3Alcohol is concentrated into 0.5g ~ 2g crude drug/1ml medicinal liquid;
D, get 5 ~ 15 parts of Eupolyphaga Seu Steleophagas, add water or C
1 ~ 3Alcohol extraction, extracting liquid filtering, filtrate is concentrated into 0.5g ~ 2g crude drug/1ml;
E, get the Eupolyphaga Seu Steleophaga that medicinal liquid that step c prepares and steps d prepare and extract the medicinal liquid mix homogeneously, concentrate drying is pulverized, the cyclodextrin of volatile oil clathrate mix homogeneously that gained extract powder and step b prepare, and get final product.
8. the described application of Chinese medicinal compound extract in preparation resisting hyperplasia of mammary glands medicine with resisting hyperplasia of mammary glands effect of claim 1 to 6.
9. the application of Chinese medicinal compound extract in preparation resisting hyperplasia of mammary glands medicine with resisting hyperplasia of mammary glands effect according to claim 7, it is characterized in that, Chinese medicinal compound extract and pharmaceutically acceptable carrier are prepared into oral liquid, granule, capsule, tablet, drop pill, the soft capsule medicine.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013103261564A CN103356967A (en) | 2013-07-30 | 2013-07-30 | Chinese herbal compound extract with effect of resisting proliferation of mammary gland, and preparation method thereof |
| CN201410122333.1A CN103908631A (en) | 2013-07-30 | 2014-03-28 | Traditional Chinese medicinal compound extract with anti-breast hyperplasia effect and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013103261564A CN103356967A (en) | 2013-07-30 | 2013-07-30 | Chinese herbal compound extract with effect of resisting proliferation of mammary gland, and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103356967A true CN103356967A (en) | 2013-10-23 |
Family
ID=49359769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013103261564A Withdrawn CN103356967A (en) | 2013-07-30 | 2013-07-30 | Chinese herbal compound extract with effect of resisting proliferation of mammary gland, and preparation method thereof |
| CN201410122333.1A Pending CN103908631A (en) | 2013-07-30 | 2014-03-28 | Traditional Chinese medicinal compound extract with anti-breast hyperplasia effect and preparation method thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410122333.1A Pending CN103908631A (en) | 2013-07-30 | 2014-03-28 | Traditional Chinese medicinal compound extract with anti-breast hyperplasia effect and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN103356967A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103908631A (en) * | 2013-07-30 | 2014-07-09 | 雷允上药业有限公司 | Traditional Chinese medicinal compound extract with anti-breast hyperplasia effect and preparation method thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105327069A (en) * | 2015-12-15 | 2016-02-17 | 无限极（中国）有限公司 | Formulation, preparation method and application of liver soothing traditional Chinese herbal medicine composition |
| CN110141634B (en) * | 2018-04-09 | 2021-10-26 | 达州市中西医结合医院 | Granule for regulating qi and eliminating stagnation and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102120020B (en) * | 2011-03-10 | 2012-04-18 | 雷允上药业有限公司 | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof |
| CN102120021B (en) * | 2011-03-11 | 2012-05-02 | 雷允上药业有限公司 | Detection method of concentrated pills for treating hyperplastic disease of breast |
| CN103356967A (en) * | 2013-07-30 | 2013-10-23 | 雷允上药业有限公司 | Chinese herbal compound extract with effect of resisting proliferation of mammary gland, and preparation method thereof |
-
2013
- 2013-07-30 CN CN2013103261564A patent/CN103356967A/en not_active Withdrawn
-
2014
- 2014-03-28 CN CN201410122333.1A patent/CN103908631A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103908631A (en) * | 2013-07-30 | 2014-07-09 | 雷允上药业有限公司 | Traditional Chinese medicinal compound extract with anti-breast hyperplasia effect and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103908631A (en) | 2014-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768534A (en) | Traditional Chinese medicinal composition with anti-tumor activity | |
| CN104826016B (en) | A kind of pharmaceutical composition and its preparation method and application for treating the proliferation of mammary gland | |
| CN102120020B (en) | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof | |
| CN103110891B (en) | Traditional Chinese medicine for treating breast hyperplasia and breast cancer | |
| CN103356967A (en) | Chinese herbal compound extract with effect of resisting proliferation of mammary gland, and preparation method thereof | |
| CN103405566A (en) | Traditional Chinese medicine composition for treating hypoovarianism and preparation method and application thereof | |
| CN105327069A (en) | Formulation, preparation method and application of liver soothing traditional Chinese herbal medicine composition | |
| CN108434399A (en) | A kind of Chinese medicine composition and preparation method of anti-curing oncoma | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN102178828A (en) | Medicament for treating proliferation of mammary gland and preparation method thereof | |
| CN105343260B (en) | The drug for treating chronic ulcerative colitis | |
| CN101129974A (en) | Traditional Chinese medicine composition for treating hepatopathy and method of preparing the same | |
| CN110499215A (en) | A kind of extracting method of olibanum essential oil and its application in preparation proliferation of mammary gland drug | |
| CN103142902B (en) | Traditional Chinese medicine composition and preparation for treating proliferative diseases of mammary gland as well as preparation method of traditional Chinese medicine composition | |
| CN103656077B (en) | A kind of Traditional Chinese medicine compound composition for the treatment of chronic kidney disease | |
| CN104983987A (en) | Traditional Chinese medicine colon dialyzate treating chronic renal failure | |
| CN104523603A (en) | Traditional Chinese medicine granules and preparation method and use thereof | |
| CN108926629A (en) | A kind of Chinese materia medica preparation improving human spermatogoa motility rate and egg penetration ability | |
| CN101224226B (en) | Novel clinical uses of big nilgiri nettle | |
| CN102188580B (en) | Externally used traditional Chinese medicine composition and cataplasm for treating lobular hyperplasia of mammary gland, and preparation methods thereof | |
| CN101371896A (en) | Pharmaceutical formulation for treating endometriosis symptom and processes for their preparation | |
| CN103720943B (en) | A kind of Chinese medicine for the treatment of gynecological bleeding and preparation method thereof | |
| CN106138990B (en) | Rupikang solid dispersion preparation and preparation method thereof | |
| CN113855754B (en) | Traditional Chinese medicine composition for removing blood stasis and stopping bleeding as well as preparation method and application thereof | |
| CN101912497B (en) | Medicament for treating bone fracture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20131023 |